Alector to Present New AL001 Data at AD/PD™ 2022
08 March 2022 - 11:00PM
Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology
company pioneering immuno-neurology, today announced an oral
presentation at the upcoming 2022 International Conference on
Alzheimer’s and Parkinson’s Diseases (AD/PDTM) being held March
15-20, 2022 virtually and in person in Barcelona, Spain.
Alector will present 12-month results from the INFRONT-2 Phase 2
open-label study of AL001 in the symptomatic cohort of
Frontotemporal Dementia patients with a C9orf72 mutation. The
Company plans to host a conference call to review these data on
March 15, 2022, at 8:30 a.m. ET.
Oral Presentation:
|
Presentation Title: Twelve-Month
Results from the INFRONT-2 Phase 2 Open-Label Study of AL001 in
Frontotemporal Dementia Patients with a C9orf72 Mutation
Presenter: Sam Jackson, M.D., MBA, Alector’s
interim Chief Medical OfficerSession
Date and Time:
Wednesday, March 16, 2022, from 11:15 a.m. – 1:15 p.m.
ETSession Title: TDP43- AND C9ORF72-RELATED
DISEASES 1On-Demand Presentation: Available
starting on Tuesday, March 15, 2022, at 3:30 a.m. ET |
Conference Call InformationAlector management
will host a conference call at 8:30 a.m. ET on March 15, 2022.
Analysts and investors are invited to participate in the conference
call by dialing (888) 705-0365 from the U.S. and Canada or (415)
817-9241 internationally and using the conference ID 6957317. The
live webcast can be accessed on the investor page of Alector’s
website at investors.alector.com. A replay of the webcast will be
available on Alector’s website approximately two hours after the
completion of the event and will be archived for up to 30 days.
About AlectorAlector is a clinical-stage
biotechnology company pioneering immuno-neurology, a novel
therapeutic approach for the treatment of neurodegenerative
diseases. Immuno-neurology targets immune dysfunction as a
root cause of multiple pathologies that are drivers of degenerative
brain disorders. Alector has discovered and is developing a broad
portfolio of innate immune system programs, designed to
functionally repair genetic mutations that cause dysfunction of the
brain’s immune system and enable the rejuvenated immune cells to
counteract emerging brain pathologies. Alector’s immuno-neurology
product candidates are supported by biomarkers and target
genetically defined patient populations in frontotemporal dementia
and Alzheimer’s disease. This scientific approach is also the basis
for the company’s immuno-oncology programs. Alector is
headquartered in South San Francisco, California. For
additional information, please visit www.alector.com.
Contacts:
1AB (media)Dan Budwick973-271-6085dan@1abmedia.com
Argot Partners (investors)Eric Kasper/Carrie McKimArgot
Partners212.600.1902alector@argotpartners.com
Alector (NASDAQ:ALEC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Alector (NASDAQ:ALEC)
Historical Stock Chart
From Apr 2023 to Apr 2024